

10 September 2025

ASX Announcement

## Firebrick receives \$250,000 R&D Tax Incentive

---

**Firebrick Pharma Limited (ASX:FRE) (Firebrick, Company)** is pleased to announce that it has received an RDTI (R&D Tax Incentive) payment of \$250,000 for eligible R&D expenditure incurred in 2024/25.

The incentive payment related to \$576,000 in reported R&D costs in the FY25 year, associated with the Company's further development of Nasodine as a broad spectrum antimicrobial agent and other new product development.

"We welcome the valuable injection of non-dilutive funds from the R&D tax incentive" said Dr Peter Molloy, Executive Director of Firebrick Pharma.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman of Firebrick Pharma.

- ENDS -

### About Firebrick (ASX:FRE)

Firebrick Pharma is a pharmaceutical innovator developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). The Company has developed and is now commercialising Nasodine® Nasal Spray (0.5% PVP-I) and has several other products in development. Firebrick has already introduced Nasodine Nasal Spray into the United States, Singapore and Fiji & South Pacific, with a launch in the Philippines expected in 2026.

**Media enquiries:**

Heidi Cuthbert  
+61 411 272 366  
[heidi.cuthbert@multiplier.com.au](mailto:heidi.cuthbert@multiplier.com.au)

**Investor enquiries:**

[Investors@firebrickpharma.com](mailto:Investors@firebrickpharma.com)